Effects of moxonidine and clonidine on renal function and blood pressure in anesthetized rats
- PMID: 9181279
Effects of moxonidine and clonidine on renal function and blood pressure in anesthetized rats
Abstract
Using classical clearance techniques, the renal effects of moxonidine and clonidine were studied in the rat. Moxonidine (0.25 and 0.5 mg/kg body weight i.v.) increased transiently fractional fluid and Na+ excretion. Similarly, clonidine in the same i.v. doses caused a sustained increase in fractional fluid excretion, but only a short lasting increase in fractional Na+ excretion that was similar to the effect of moxonidine. Water diuresis experiments showed that the agonists mostly exert their actions within the proximal tubule. Antagonists such as idazoxan and yohimbine did not change fractional fluid excretion and Na+ excretion by their own. Both, the nonselective imidazoline/alpha 2-adrenoceptor antagonist idazoxan and the pure alpha 2-adrenoceptor antagonist yohimbine attenuated the moxonidine induced effects on fractional fluid excretion and Na+ excretion. The clonidine induced increase in fractional fluid and Na(+)-excretion was inhibited by yohimbine and desmopressin only. The effects on systemic blood pressure after moxonidine or clonidine application were similar. The initial blood pressure increases after moxonidine application, however, was less than with clonidine, whereas the hypotensive potency was more pronounced. Similar to the effects on kidney function, idazoxan and yohimbine had no influence on systemic blood pressure by themselves. Immediately after moxonidine application, a short lasting increase in renal plasma flow and glomerular filtration rate could be observed. Our results demonstrate, that moxonidine exerts renal effects, which are different from those of clonidine. At present time, renal effects mediated by imidazoline receptors and alpha 2-adrenoceptors cannot be clearly distinguished.
Similar articles
-
Renal and blood pressure effects of moxonidine and clonidine in spontaneously hypertensive rats.Clin Nephrol. 1997 Dec;48(6):346-52. Clin Nephrol. 1997. PMID: 9438092
-
Effects of moxonidine and clonidine on potassium excretion in Sprague-Dawley rats.Pharmacol Res. 1999 May;39(5):357-61. doi: 10.1006/phrs.1998.0449. Pharmacol Res. 1999. PMID: 10328993
-
Involvement of central alpha1- and alpha2-adrenoceptors on cardiovascular responses to moxonidine.Eur J Pharmacol. 2007 Jun 1;563(1-3):164-71. doi: 10.1016/j.ejphar.2007.02.002. Epub 2007 Feb 16. Eur J Pharmacol. 2007. PMID: 17382316
-
Adrenergic blocking agents and the kidney.J Clin Hypertens. 1985 Sep;1(3):199-221. J Clin Hypertens. 1985. PMID: 2872278 Review.
-
Pharmacology and clinical use of moxonidine, a new centrally acting sympatholytic antihypertensive agent.J Hum Hypertens. 1997 Aug;11 Suppl 1:S29-45. J Hum Hypertens. 1997. PMID: 9321737 Review.
Cited by
-
Urinary responses to acute moxonidine are inhibited by natriuretic peptide receptor antagonist.Br J Pharmacol. 2005 May;145(1):50-6. doi: 10.1038/sj.bjp.0706146. Br J Pharmacol. 2005. PMID: 15700025 Free PMC article.
-
The CLOSED trial; CLOnidine compared with midazolam for SEDation of paediatric patients in the intensive care unit: study protocol for a multicentre randomised controlled trial.BMJ Open. 2017 Jun 21;7(6):e016031. doi: 10.1136/bmjopen-2017-016031. BMJ Open. 2017. PMID: 28637741 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical